A research team has developed an innovative nanomotor-based strategy to improve immunotherapy for bladder cancer. The study, ...

Adjuvant BCG therapy of superficial bladder cancer remains the most successful immunotherapy for ... intravesical instillations of bacillus Calmette–Guerin (BCG), introduced in 1976, has ...

They enrolled and treated 32 patients with stage T2-T4a disease with no metastases or lymph node involvement who had not ...

The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...

Although the use of intravesical immunotherapy for reducing tumor progression or as maintenance therapy is controversial, bacillus Calmette–Guérin has demonstrated significant benefit for tumor ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA ...

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors ...

IBRX), a leading immunotherapy company, today announced compelling new data from its ongoing QUILT 3.032 study. As of November 2024, 100 patients with Bacillus Calmette-Guérin (BCG)-unresponsive ...

ImmunityBio, Inc.’s IBRX share price has surged by 15.03%, which has investors questioning if this is right time to sell.

A study led by the Institute for Bioengineering of Catalonia (IBEC) and Pohang University of Science and Technology (POSTECH) in South Korea describes the development of urea-powered nanomotors that ...

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...